IV Nutrient Therapy & Myers Cocktail: Evidence Review

Quick answer: Intravenous (IV) nutrient therapy bypasses gastrointestinal absorption limitations, achieving plasma concentrations of vitamins, minerals, and antioxidants 5–50 times higher than oral dosing permits. High-dose IV vitamin C (IVC) at 25–75g produces pro-oxidant effects selectively toxic to cancer cells through extracellular H2O2 generation. The Myers Cocktail — magnesium, calcium, B vitamins, and vitamin C — has the longest clinical track record, with the most robust evidence for fibromyalgia, migraine, asthma, and acute infections.

Why IV? The Absorption Ceiling Problem

Oral supplement absorption is governed by intestinal transporters with finite capacity, hepatic first-pass metabolism, and the biochemical milieu of the gut lumen. Vitamin C illustrates the limitation perfectly: at oral doses of 200 mg/day, plasma ascorbate reaches approximately 80 μmol/L (near saturation of intestinal sodium-dependent vitamin C transporters). Increasing the oral dose to 10g/day raises plasma levels only marginally — to approximately 220 μmol/L — because the transporters are already saturated, and excess vitamin C causes osmotic diarrhea through the unabsorbed fraction in the colon.

Intravenous delivery bypasses all these limitations. IV vitamin C at 25g over 90 minutes achieves plasma concentrations of 1,000–5,000 μmol/L — 20–60 times the maximum achievable orally. At these plasma concentrations, vitamin C acts as a pro-oxidant in the extracellular space (paradoxical to its intracellular antioxidant function) — generating hydrogen peroxide in tissue at concentrations that overwhelm catalase in cancer cells (which have low catalase activity) while normal cells with adequate catalase remain protected.

The same absorption ceiling applies to magnesium, glutathione, B vitamins, phosphatidylcholine, and NAD+ — all of which have oral absorption limits that prevent achievement of therapeutically meaningful tissue concentrations in patients with GI dysfunction, malabsorption, or the need for acute therapeutic levels in conditions like migraine, infection, or fatigue crisis.

The Myers Cocktail: Foundation of IV Nutrient Therapy

The Myers Cocktail was developed by Baltimore physician John Myers in the 1970s and later documented and popularized by Alan Gaby, MD, whose comprehensive 2002 case series review in Alternative Medicine Review remains the primary clinical reference for the protocol. The original formulation includes magnesium chloride (or magnesium sulfate), calcium gluconate, vitamin B12 (hydroxocobalamin or methylcobalamin), B-complex vitamins, vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), and vitamin C, delivered intravenously in sterile water or normal saline over 20–45 minutes.

Gaby’s case series documented patient outcomes across a remarkably diverse range of conditions: asthma acute attacks, chronic fatigue syndrome, fibromyalgia, seasonal allergic rhinitis, acute viral infections, cardiovascular disease, depression, athletic performance, and migraine. The breadth of response reflects the fundamental role of these nutrients in mitochondrial energy production, neurotransmitter synthesis, and immune function — making the Myers Cocktail broadly applicable to patients with multiple nutrient deficiencies or high metabolic demand.

The best controlled trial of IV magnesium and nutrients is the asthma literature: IV magnesium sulfate (2g over 20 minutes) is standard emergency department therapy for severe acute asthma not responding to bronchodilators, supported by multiple Cochrane reviews demonstrating significant improvement in pulmonary function and reduction in hospitalization rates. This validated the central pharmacological logic of the Myers Cocktail — IV magnesium achieves bronchodilation and smooth muscle relaxation at concentrations not achievable orally.

High-Dose Intravenous Vitamin C (IVC)

Cancer Adjunct: The Riordan Protocol

Linus Pauling and Ewan Cameron published provocative data in the 1970s suggesting high-dose vitamin C (oral and IV) extended survival in terminal cancer patients. Subsequent oral vitamin C trials failed to replicate the benefit — now understood to reflect the critical distinction: oral administration cannot achieve the pharmacological plasma concentrations required for the pro-oxidant anti-cancer mechanism. Only intravenous administration achieves these levels.

The Riordan Clinic in Wichita, Kansas developed the most rigorously documented IVC protocol for cancer. The mechanism at doses of 25–75g IV: ascorbate at millimolar extracellular concentrations reacts with free iron and copper to generate hydrogen peroxide (H2O2) in the extracellular space surrounding tumor cells. Tumor cells have markedly reduced catalase activity compared to normal cells — they cannot neutralize this H2O2 load, leading to selective oxidative damage and apoptosis. Normal cells with adequate catalase detoxify the H2O2 and are protected.

Padayatty et al. (2006, CMAJ) documented three case reports of unexpected tumor regression in patients receiving IVC. Hoffer et al. (2008, Annals of Oncology) conducted a Phase I trial demonstrating IVC safety and tolerability in cancer patients. Polireddy et al. (2017, Scientific Reports) demonstrated IVC sensitized pancreatic cancer cells to gemcitabine in both cell culture and mouse models. A comprehensive systematic review (Jacobs et al., 2015, Oncotarget) concluded the evidence warranted larger Phase II/III trials, though these remain limited by funding challenges for non-patentable interventions.

IVC is not approved by the FDA as a cancer treatment and should not replace standard oncology care. It is most evidence-supported as a complement to chemotherapy and radiation — potentially reducing treatment side effects, improving quality of life, and through its selective pro-oxidant mechanism, enhancing tumor cell sensitivity to conventional treatment. All cancer patients considering IVC must disclose it to their oncologist due to theoretical interactions with certain chemotherapy agents.

Infection Support and Immune Function

Vitamin C is required for neutrophil oxidative burst (the mechanism by which immune cells kill bacteria), T-cell proliferation, natural killer cell activity, and interferon production. Plasma vitamin C drops precipitously during acute infection and critical illness — falling below deficiency levels in ICU patients within 24–48 hours of admission. Replenishing vitamin C during infection restores these immune functions.

The CITRIS-ALI trial (Fowler et al., 2019, JAMA) randomized 167 ICU patients with sepsis-associated ARDS to IV vitamin C (200 mg/kg/day for 4 days) versus placebo. The primary endpoints (SOFA score and inflammatory markers) showed non-significant trends; however, 28-day mortality was significantly reduced (29.8% control vs. 16.3% IVC, p=0.03) — a secondary finding that has driven ongoing larger trials. The LOVIT trial (2022, NEJM) used a different dosing protocol and found no benefit — highlighting the importance of dose, timing, and patient selection. The sepsis/critical illness IVC field remains scientifically active and unsettled.

For outpatient functional medicine use, IVC during acute viral infections (influenza, EBV, COVID) at doses of 10–25g is commonly employed based on mechanistic rationale and clinical experience, with very low risk given the safety profile. Inpatient use for critical illness requires larger trials before standard-of-care adoption.

IV Glutathione

Glutathione (GSH) — a tripeptide of glutamate, cysteine, and glycine — is the body’s master antioxidant and primary detoxification cofactor. Plasma glutathione decreases with aging, chronic disease, chemical exposure, and oxidative stress. Oral glutathione supplementation has poor bioavailability (degraded to constituent amino acids by gut proteases), making IV delivery the most effective approach for rapid acute repletion.

The most significant clinical evidence for IV glutathione is in Parkinson’s disease. Sechi et al. (1996, Progress in Neuropsychopharmacology and Biological Psychiatry) reported a small open-label trial (n=9) in which IV glutathione (600 mg twice daily for 30 days) produced significant improvement in disability scores and symptom severity in Parkinson’s patients. The rationale: Parkinson’s patients have markedly depleted substantia nigra glutathione levels, and IV glutathione may protect remaining dopaminergic neurons from oxidative damage. A subsequent small RCT (Hauser et al., 2009) showed non-significant trends. Larger trials using intranasal glutathione delivery (which better penetrates the CNS) are ongoing at the Parkinson’s Research Institute.

IV glutathione is widely used in functional medicine for detoxification support (heavy metal chelation adjunct, pesticide exposure, chemical sensitivity), immune modulation, skin brightening (glutathione inhibits melanin synthesis via tyrosinase inhibition — the basis for its use in skin lightening), and general antioxidant repletion in patients with chronic illness. Standard outpatient doses: 600–1,200 mg IV push over 10–15 minutes, 1–3x weekly. Common side effects: temporary skin flushing, garlic-like odor from sulfur metabolites; rare serious reactions occur with too-rapid infusion rate.

IV NAD+: The Mitochondrial Infusion

Nicotinamide adenine dinucleotide (NAD+) is the electron carrier central to mitochondrial ATP production via the electron transport chain, and the substrate for sirtuin longevity enzymes (SIRT1–7) and PARP DNA repair enzymes. NAD+ declines approximately 50% between ages 40 and 60, and more rapidly in chronic disease, alcohol use disorder, and under conditions of chronic oxidative stress.

Oral NAD+ precursors (NMN, NR) restore tissue NAD+ levels effectively in most patients. IV NAD+ bypasses the oral route entirely — plasma NAD+ rises dramatically within minutes of infusion, and the high plasma gradient drives NAD+ into cells across the gradient. The claimed clinical applications of IV NAD+ include: addiction and withdrawal support (reducing cravings and withdrawal symptoms in alcohol and opioid dependence), acute fatigue and cognitive restoration, post-COVID brain fog, athletic recovery, and longevity protocols.

The evidence base for IV NAD+ is weaker than for IVC or IV glutathione. Published human trials are sparse, though the mechanistic basis is strong — NAD+ is genuinely depleted in addiction, critical illness, and aging, and IV repletion achieves higher acute plasma levels than oral approaches. A pilot study at the Springfield Wellness Center (Louisiana) documented significant reduction in withdrawal symptoms and cravings with IV NAD+ in patients with substance use disorders, leading to ongoing clinical interest. The field lacks the controlled trial infrastructure of pharmaceutical drug development, largely because NAD+ is not patentable.

Common IV NAD+ protocols: 250–500 mg NAD+ per infusion, over 2–4 hours (faster rates cause flushing, chest tightness, and nausea — patient-specific rate titration is required). Typical courses: 4–10 consecutive daily infusions for acute indications (addiction, brain fog), followed by monthly maintenance infusions. Cost: $200–$500 per session depending on dose and facility. Oral NMN (500 mg/day) and NR (1,000 mg/day) are substantially cheaper and produce meaningful NAD+ restoration for most patients — IV NAD+ is reserved for cases requiring rapid acute repletion or confirmed oral non-response.

IV Phosphatidylcholine (PC)

Phosphatidylcholine is the dominant phospholipid in cell membranes — constituting 40–50% of the phospholipid bilayer in most human cell types. Membrane phosphatidylcholine content declines with aging and is depleted in conditions of chronic chemical exposure, liver disease, and neurodegenerative disorders. IV phosphatidylcholine (as Plaquex, a formulation of soy-derived phosphatidylcholine in deoxycholate) has been used in European integrative medicine since the 1960s, primarily for atherosclerosis, liver disease, and cognitive decline.

Mechanistically, IV PC replaces oxidized, stiffened phospholipids in cell membranes with intact, flexible phospholipids — restoring membrane fluidity, receptor function, and transport efficiency. In atherosclerosis, PC facilitates reverse cholesterol transport and may contribute to plaque stabilization. In liver disease (alcoholic steatohepatitis, NASH), IV PC has the strongest evidence base — European multicenter trials demonstrated significant improvement in liver histology with Plaquex infusions in alcoholic liver disease (Knuchel 1989, Lieber 1994). The mechanism involves hepatocyte membrane repair and enhancement of VLDL assembly and cholesterol excretion.

Safety and Provider Standards

IV nutrient therapy is generally safe when administered by trained providers following pharmaceutical-grade compounding and sterile technique standards. Serious adverse events are rare but reported:

Magnesium toxicity: IV magnesium administered too rapidly (particularly in patients with renal insufficiency) can produce cardiac conduction abnormalities, hypotension, and — at very high levels — respiratory depression. Standard Myers Cocktail magnesium doses (400–800 mg) are safe with normal renal function and appropriate administration rate (minimum 15–20 minutes for the magnesium component).

Anaphylaxis: Rare but reported with IV B vitamins (particularly thiamine) — epinephrine availability and trained provider response capability is required for all IV nutrient administration.

Glucose-6-phosphate dehydrogenase (G6PD) deficiency: High-dose IVC is absolutely contraindicated in G6PD deficiency — the oxidative stress from high-concentration ascorbate can trigger hemolytic anemia in G6PD-deficient red blood cells. G6PD testing is mandatory before initiating IVC protocols above 10g.

Osmolarity and vein irritation: High-osmolarity solutions can cause phlebitis if administered too rapidly or through small peripheral veins. IVC above 25g should be administered through a large-bore IV, ideally with dilution in 500 mL normal saline to reduce osmolarity. Persistent phlebitis warrants switching to a larger vein or considering port placement for patients receiving frequent high-dose IVC.

Provider standards: IV nutrient therapy should be administered in a clinical setting with physician oversight, pharmaceutical-grade compounding (USP 795/797 compliant), sterile technique, proper vein assessment, and emergency response capability. IV nutrient bars or wellness spas without physician oversight and emergency response capability represent a quality and safety risk, particularly for high-dose protocols. All providers should perform baseline labs (renal function, G6PD for IVC, CBC) before initiating high-dose protocols.

FAQs About IV Nutrient Therapy

How often should you get IV nutrient therapy?
Frequency depends entirely on the indication and patient response. For acute conditions — migraine, acute infection, asthma exacerbation — 1–3 treatments over a short period may resolve the acute episode. For chronic conditions like fibromyalgia, CFS, or chronic fatigue, an induction phase of 4–8 weekly treatments followed by monthly maintenance is typical. Healthy individuals using IV nutrient therapy as a longevity adjunct typically do quarterly IV infusions coinciding with seasonal changes. Athletes using IVC or Myers Cocktail for recovery commonly schedule infusions around competition cycles. Individual response assessment after the first 4–6 treatments should guide frequency decisions.

Is IV vitamin C safe with chemotherapy?
The safety of IVC during chemotherapy is drug-specific and requires oncology consultation. IVC may enhance the effect of some chemotherapy agents (cisplatin, paclitaxel, gemcitabine) while potentially blunting others. A 2014 review by Simone et al. in Anticancer Research concluded that the evidence does not support concern about IVC reducing chemotherapy efficacy for most standard regimens. However, IVC should not be used on the same day as chemotherapy administration, and must be disclosed to and approved by the treating oncologist in all cases.

Can IV nutrient therapy help with long COVID?
Long COVID pathophysiology includes mitochondrial dysfunction, chronic oxidative stress, NAD+ depletion, endothelial dysfunction, and immune dysregulation — all theoretical targets of IV nutrient therapy. IV NAD+ (for mitochondrial support and brain fog), IV vitamin C (oxidative stress reduction and immune modulation), and IV glutathione (antioxidant repletion and detoxification support) are each being used in functional medicine long COVID protocols. Published clinical trial evidence specifically for IV nutrients in long COVID is limited, though several trials are registered. Case series and clinical experience suggest IV NAD+ may be particularly helpful for long COVID brain fog and fatigue.

Is IV nutrient therapy covered by insurance?
For the most part, IV nutrient therapy for functional medicine indications is not covered by insurance in the United States. IV magnesium for acute severe asthma in the emergency department is standard covered care. High-dose IV vitamin C for adjunct cancer support is sometimes covered when administered in an oncology center. For all other indications — fibromyalgia, CFS, fatigue, longevity — it is self-pay. Costs range from $100–$200 for standard Myers Cocktail to $250–$500 per session for high-dose IVC or IV NAD+. Health savings accounts (HSAs) and flexible spending accounts (FSAs) can often be used for IV nutrient therapy with physician prescription documentation.

If you are interested in IV nutrient therapy for chronic fatigue, immune support, cancer adjunct, recovery from infection, or as part of a comprehensive longevity protocol, a thorough functional medicine evaluation establishes your baseline nutrient status, identifies deficiencies, and determines which IV protocols are most appropriate for your individual case. Contact our office at (810) 206-1402 to schedule a consultation.

IV Nutrient Therapy: Myers Cocktail, High-Dose Vitamin C, and IV NAD+ Evidence Guide